

August 13, 2012



Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update

SOUTH EASTON, Mass., Aug. 13, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2012 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone or through a live web-cast. The teleconference and web-cast information is provided below:

Date: Tuesday, August 14, 2012

Time: 4:30 p.m. Eastern Daylight Time (EDT)

To attend this teleconference via telephone:

Dial-in: 800-875-3456

Passcode (to be given to the operator): VS67260

For those unable to participate in the teleconference, a replay will be available approximately one hour after the call ends through September 14, 2012, and will be accessible through the Company's website.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated \$6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following links:

<http://www.pressurebiosciences.com>

Investor Contacts:

Richard T. Schumacher, President & CEO
Joseph Damasio, Jr., V.P. of Finance

Pressure BioSciences, Inc.
(T) 508-230-1828

SOURCE Pressure BioSciences, Inc.